EP0907318A1 - Antioxidierende verbindung - Google Patents
Antioxidierende verbindungInfo
- Publication number
- EP0907318A1 EP0907318A1 EP97922494A EP97922494A EP0907318A1 EP 0907318 A1 EP0907318 A1 EP 0907318A1 EP 97922494 A EP97922494 A EP 97922494A EP 97922494 A EP97922494 A EP 97922494A EP 0907318 A1 EP0907318 A1 EP 0907318A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bucindolol
- treatment
- pharmaceutically acceptable
- acceptable salt
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a new medical use of, and method of treatment using, the compound of Formula I, as an oxygen radical scavenger, or as an antioxidant, for the protection of vital organs, particularly the organs of the cardiovascular system e.g. the heart, the central nervous system, and the renal system, from oxidative tissue damage.
- the present invention provides a new use for the compound of this invention for making pharmaceutical compositions useful in the prevention of organ reperfusion injury, particularly cardioprotection, that is protection of the cardiovascular system from traumatic and post-traumatic injury associated with myocardial infarction, neuroprotection, that is protection of the central nervous system from traumatic and post-traumatic injury associated with stroke, and renal protection.
- the present invention provides a new medical use for the compound of Formula I as an oxygen radical scavenger or as an antioxidant for the protection of vital organs from oxidative damage.
- the present invention provides a new use for the compound of this invention to make pharmaceutical compositions useful in the prevention of organ reperfusion injury, particularly useful in cardioprotection, neuroprotection and renal protection.
- the present invention also provides a method of treatment for prevention of oxidative tissue damage to organs afflicted with disease-induced ischemic trauma, particularly cardioprotection, neuroprotection and renal protection, in mammals comprising internally administering to a mammal, preferably a human, in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
- a mammal preferably a human
- the preferred pharmaceutically acceptable salt of the Formula I compound is the hydrochloric acid salt.
- Bucindolol which is 2-[2-hydroxy-3-[[2-(lH-indol-3-yl)-l,l- dimethylethyl]amino]propoxy]-benzonitrile, is the compound of Formula I and it has the following structure:
- Bucindolol may be used as its free base or as a pharmaceutically acceptable salt thereof.
- the preferred pharmaceutically acceptable salt is the hydrochloric acid salt.
- ischemic organ trauma as in acute myocardial infarction or stroke, a high proportion of ischemic organ cells become irreversibly damaged and necrotic, the extent of injury being dependent upon the length of time that the trauma, e.g. the arterial occlusion, persists.
- the protection of myocardial cells from such damage and necrosis during occlusion occurring during myocardial infarction and post- infarction reperfusion is essential to achieving the therapeutic goal of restoration of cardiac function; here and throughout this application this property is referred to by the term "cardioprotection" and its synonyms.
- central nervous system neurons The protection of the central nervous system neurons from such damage and necrosis during occlusion occurring in stroke and post-traumatic reperfusion is essential to achieving the therapeutic goal of restoration of neurological function; here and throughout this application this property is referred to by the term "neuroprotection" and its synonyms.
- ⁇ -adrenoceptor antagonists for instance propranolol
- ⁇ -adrenoceptor antagonists for instance propranolol
- they also often have undesireable side effects such as bradycardia, elevated disatolic blood pressure and total peripheral resistance cardiodepression.
- Bucindolol is effective as a cardioprotective agent at antihypertensive doses which unexpectedly minimize these consequences.
- the combination of ⁇ -adrenoceptor blocking and vasodilatory properties of Bucindolol provides cardioprotection during and after acute myocardial infarction.
- the compound of the present invention is especially useful in cardioprotection, that is, prevention of acute myocardial infarction, and reduction of morbidity resulting from the sequelae of myocardial infarction and reperfusion.
- the compound of the present invention is especially useful in neuroprotection, that is, prevention of stroke, and reduction of morbidity resulting from the sequelae of stroke.
- Bucindolol exhibits cardioprotection, and is especially useful for providing a beneficial cardioprotective effect by prevention of oxidative tissue damage in ischemic human myocardium; thus this compound has utility as adjunctive therapy following myocardial infarction.
- Chronic administration of this compound can both reduce the risk of acute myocardial infarction in individuals at risk thereof as well as provide adjunctive therapy by reducing the magnitude of oxidative tissue damage following an ischemic cardiac event. Because hypertensive individuals are at increased risk of stroke, the cardioprotective use of the present compound at appropriate dosing regimens in combination with antihypertensive therapy significantly reduces the risk of acute myocardial infarction, reinfarction, the area of infarcted tissue should reinfarction occur, and sudden cardiac death in such patients.
- Bucindolol exhibits neuroprotection, and is especially useful for protecting cerebral tissue from stroke and neurotrauma and for preventing oxidative tissue damage of ischemic human cerebral tissue following occurrence of an ischemic event such as stroke or cerebral trauma.
- chronic administration of this compound can both reduce the risk of cerebral ischemia or stroke in individuals at risk thereof as well as provide adjunctive therapy by reducing the magnitude of oxidative tissue damage following an ischemic cerebral event.
- the neuroprotective use of the present compound at appropriate dosing regimens in combination with antihypertensive therapy significantly reduces the risk of stroke, and the sequelae of stroke in such patients.
- Bucindolol is useful for cardioprotection, neuroprotection and renal protection in humans according to the present invention at dosages ranging from about 25-400 mg/day p.o.
- the present invention also provides a method of treatment for prevention of oxidative tissue damage to organs afflicted with disease-induced ischemic trauma in mammals comprising internally administering to a mammal, preferably a human, in need thereof an effective amount of Bucindolol, or a pharmaceutically acceptable salt thereof.
- the preferred pharmaceutically acceptable salt is the hydrochloric acid salt.
- Bucindolol may be conveniently prepared as described in GB Patent No. 2001633.
- compositions of Bucindolol for cardioprotective, neuroprotective and renal protective uses according to the present invention may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
- the liquid formulation is generally a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
- Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as ethanol, polyvinyl-pyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
- these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration.
- Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
- Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, ethanol, and water.
- Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
- the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit.
- the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
- a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension.
- Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
- Bucindolol The antioxidant activity of Bucindolol can be determined using a standard lipid peroxidase assay. The details of this in vitro assay are found in Feuerstein, et al., J. Hypertension. 11 (Supp. 4): S41-48 (1993).
- the figure represents a dose-response relationship of the neuroprotective effect of Carvedilol and Bucindolol in vitro.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1647696P | 1996-04-29 | 1996-04-29 | |
US16476P | 1996-04-29 | ||
PCT/US1997/007037 WO1997040680A1 (en) | 1996-04-29 | 1997-04-25 | Antioxidant compound |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0907318A1 true EP0907318A1 (de) | 1999-04-14 |
EP0907318A4 EP0907318A4 (de) | 2000-02-02 |
Family
ID=21777334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97922494A Withdrawn EP0907318A4 (de) | 1996-04-29 | 1997-04-25 | Antioxidierende verbindung |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0907318A4 (de) |
JP (1) | JP2000510110A (de) |
WO (1) | WO1997040680A1 (de) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4234595A (en) * | 1977-07-13 | 1980-11-18 | Mead Johnson & Company | 3-Indolyl-tertiary butylaminopropanols |
WO1994012178A1 (en) * | 1992-12-01 | 1994-06-09 | Smithkline Beecham Corporation | Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405863A (en) * | 1992-12-01 | 1995-04-11 | Smithkline Beecham Corporation | Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds |
-
1997
- 1997-04-25 EP EP97922494A patent/EP0907318A4/de not_active Withdrawn
- 1997-04-25 JP JP09539096A patent/JP2000510110A/ja active Pending
- 1997-04-25 WO PCT/US1997/007037 patent/WO1997040680A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4234595A (en) * | 1977-07-13 | 1980-11-18 | Mead Johnson & Company | 3-Indolyl-tertiary butylaminopropanols |
WO1994012178A1 (en) * | 1992-12-01 | 1994-06-09 | Smithkline Beecham Corporation | Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds |
Non-Patent Citations (5)
Title |
---|
BRISTOW, O'CONNELL, GILBERT: "dose-response of chronic beta-blocker treatment in heart failure..." CIRCULATION, no. 89, 1994, pages 1632-1642, XP000863212 * |
G Z FEUERSTEIN ET AL: "Carvedilol Update III. Rationale for use in congestive heart failure" DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD,ES,J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, vol. 31, no. SUPPL. F, page 1-23 XP002039368 ISSN: 0025-7656 * |
GILBERT E M, ANDERSON J L: "long term beta blocker vasodilator therapy improved cardiac functioning in idiopathic" AMER J MED, vol. 88, 1990, pages 223-229, XP000862858 * |
See also references of WO9740680A1 * |
WOODLEY,GILBERT,ANDERSON: "beta-blockade with bucindolol in heart failure caused by ischemic versus..." CIRCULATION, no. 84, 1991, pages 2426-2441, XP000863213 * |
Also Published As
Publication number | Publication date |
---|---|
EP0907318A4 (de) | 2000-02-02 |
WO1997040680A1 (en) | 1997-11-06 |
JP2000510110A (ja) | 2000-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU675481B2 (en) | Antioxydant cardioprotective use of, and method of treatmentusing, hydroxycarbazole compounds | |
HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
WO2005084392A2 (en) | 4-methylpyrazole formulations for inhibiting ethanol intolerance | |
EP1558256B1 (de) | Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden | |
CA2411882A1 (en) | Solid valsartan pharmaceutical compositions | |
US5508308A (en) | Use of pyruvylglycine to treat ischemia/reperfusion injury following myocardial infarction | |
MXPA06014885A (es) | Nueva asociacion de un ihnibidor de la corriente sinusal if y de un inhibidor de la enzima de conversion y las composiciones farmaceuticas que la contienen. | |
US20020107279A1 (en) | Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds | |
AU673882B2 (en) | Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds | |
EP0907318A1 (de) | Antioxidierende verbindung | |
JP2007536256A (ja) | 心臓損傷の処置のためのピロロキノリンキノン薬およびその使用方法 | |
US20050267124A1 (en) | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors | |
US4686225A (en) | Vinpocetine for pulmonary hemorrhage and edema | |
US20050267143A1 (en) | Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof | |
EP0303357B1 (de) | 4-Amino-6,7-dimethoxy-2-(6,7-dimethoxy-1,2,3,4-tetrahydroiso-quinol-2-yl)quinoline zur (Behandlung von Herz-Arrythmien). | |
EP2052735B1 (de) | Pharmazeutische Zusammensetzung und Kit enthaltend Anserin zur schnellen Reduzierung des Harnsäureanteils im Blut | |
WO2000025773A1 (en) | Pharmaceutical combination of mildronate and enalapril | |
WO2005112940A1 (en) | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and pde v inhibitors | |
US4716177A (en) | Tolrestat for inhibition of weight gain | |
IT201900006624A1 (it) | Combinazione di canrenone e enalapril per uso nella terapia dei pazienti diabetici. | |
Yoshikawa et al. | Antioxidants in gastric mucosal injury | |
Mayrleitner | E047/1 | |
WO1992002224A1 (en) | Antiparkinson mao reversible inhibitor | |
JPH04503806A (ja) | 治療剤 | |
WO1996022096A1 (en) | Pharmaceutical compositions containing bisaramil inhibiting radical production and process for preparing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981023 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE ES FR GB IT LI NL |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19991222 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): BE CH DE ES FR GB IT LI NL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20000301 |